Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC ...

Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...